Ongoing treatment(s)-Biological therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Ending trastuzumab treatment in patients with HER2-positive metastatic breast cancer who are in radiological complete remission

Posted by on Oct 20, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission.   This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...

Read More

Epidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for lung cancer

Posted by on Sep 26, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with non-small cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some...

Read More

Epidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for colorectal cancer

Posted by on Sep 26, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with colorectal cancer receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some background...

Read More

Searching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...

Read More

Stopping TKI treatment in chronic myeloid leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study was an update on the guidelines of stopping tyrosine kinase inhibitor (TKI) therapy in the treatment of chronic myeloid leukemia (CML). New guidelines confirm the safety of stopping TKI therapy in patients with CML. Some background Chronic myeloid leukemia is often treated with TKI therapy. These are drugs which...

Read More

Looking for patients with lung cancer to test a new immunotherapy combination

Posted by on Apr 24, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with solid tumors, including lung cancer. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of limited...

Read More

Rate of deep molecular response in chronic myeloid leukemia treated with nilotinib

Posted by on Apr 15, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the rate of deep molecular response in patients with newly diagnosed chronic myeloid leukemia who were treated with nilotinib. This study concluded that good molecular response rates are seen in these patients. Some background Molecular response (MR) is a measure of the levels of BCR-ABL1 gene in leukemia...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More